Hyundai Bioscience Co., Ltd.

KOSDAQ 048410.KQ

Hyundai Bioscience Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2023: -32.03%

Hyundai Bioscience Co., Ltd. Return on Equity (ROE) is -32.03% for the year ending December 31, 2023, a -17.99% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Hyundai Bioscience Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2022 was -27.14%, a 16.65% change year over year.
Hyundai Bioscience Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2021 was -32.57%, a -106.35% change year over year.
Hyundai Bioscience Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2020 was -15.78%, a -1,065.92% change year over year.
Hyundai Bioscience Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2019 was 1.63%, a -74.75% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

KOSDAQ: 048410.KQ

Hyundai Bioscience Co., Ltd.

CEO	Jong-Won Choi
IPO Date	Aug. 28, 2002
Location	South Korea
Headquarters	Academic Cooperation Building
Employees	63
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Hyundai Bioscience Co., Ltd., a biotechnology company, develops and commercializes bio-fusion technology for delivering active ingredients to human body. The company provides Vitabrid C12, a new-conceptual vitamin C product that delivers active vitamin C into the skin. It also develops organic-inorganic hybrid technology, a drug delivery system technology that allows the selective and effective delivery of active substances on the target area in combination with bio-friendly minerals, as well as in anticancer drug carrier technology. The company was founded in 2000 and is based in Seoul, South Korea.

Key trends

Past 5 years